Biopharmaceutical Company Expands Product Portfolio, Fosters Patient Support

Strategic Insights -

We are a commercial-stage biopharmaceutical company with a strategic focus on in-licensing and developing products that treat rare diseases, especially those in the neuromuscular and neurological spaces. However, following a 2021 decision to broaden and diversify our product portfolio, we have been actively exploring opportunities to acquire companies with drug products in development or to in-license products that fit our expanded criteria.

The company has made significant strides in expanding its presence globally, particularly in the Asian market. In June 2021, we announced a positive decision in a Canadian court that quashed the NOC previously issued for Ruzurgi (R) in the country. Additionally, we have reached an agreement with Japanese regulatory authorities as to the scope of the clinical trial required to be completed before an application can be submitted to commercialize FIRDAPSE in Japan. Furthermore, DyDo Pharma, our collaborator, initiated a Phase 3 registrational study in Japan in December 2021 to evaluate the efficacy and safety of FIRDAPSE (R).

Our team has also been actively working with patients and physicians to ensure access to our products for those suffering from rare diseases. In response to the COVID-19 pandemic, we developed an array of financial assistance programs to reduce patient expenses for our medication, such as FIRDAPSE (R). As part of our commitment to supporting patients and their caregivers, we sponsor advocacy organizations that provide education and support to those affected by rare diseases.

Key Takeaways:

  • The company has broadened its focus to include the development of products for rare diseases outside of the neuromuscular space, aiming to build a more diversified portfolio.
  • In 2021, we made a strategic decision to expand and diversify our product portfolio, with a focus on acquiring or in-licensing products in the rare disease marketplace.
  • The company's efforts in expanding its international presence are yielding tangible results, including the positive Canadian court decision for Ruzurgi (R) and the ongoing Phase 3 registrational study in Japan.
  • We have a dedicated team that works to ensure that our products reach the patients who need them most, a commitment that is reflected in our financial assistance programs for FIRDAPSE (R) patients.
  • Our collaboration with DyDo Pharma, a key Japanese pharmaceutical company, reflects our strategic efforts to position our products in the global market.
  • Additional patent applications for FIRDAPSE are underway, with three related patents allowed by the USPTO in March 2022.

Statistics:

  • Cash and investments totalled $198 million at March 31, 2022.
  • FIRDAPSE sales generated revenue in the fiscal quarter ended March 31, 2022.
  • The company expects fluctuations in revenue from the Endo collaborative agreement and the DyDo license agreement in future periods.
  • As of March 31, 2022, we had cash and investments of approximately $198 million, sufficient to support operations for at least the next 12 months.

Sources:

  • Edgar Online via COMTEX
  • "Management's Discussion and Analysis of Financial Condition and Results of Operations"
  • DyDo Pharma press release
  • Japanese regulatory authority agreement
  • USPTO patents
  • Annual Report of the company